Literature DB >> 3591816

Epidemiologic implications of changes in the influenza virus genome.

A P Kendal.   

Abstract

Among the molecular maneuvers that enable the influenza virus to survive are antigenic variation and functional alterations. Two kinds of minor antigenic variations, producing new strains within type A virus subtypes, have been discovered: antigenic drift, in which the amino acid sequences of the antigens are changed; and antigenic camouflage, in which the antigens are glycosylated. Both kinds of variation are caused by mutations in the viral genome. These mutations produce slightly changed antigens, which many existing antibodies cannot recognize. Major antigenic variations (so-called antigenic shift) are produced by gene reassortment. Two subtypes, coinfecting a host, can reassort their eight ribonucleoprotein gene segments into as many as 256 different combinations. Such recombinations can produce new viruses with the potential for transmission in humans, but whose surface antigens are completely unmatched by antibodies in the population, permitting a pandemic to occur. Functional changes, caused by mutations, alter the interactions between the virus and the host, including virus binding to host receptor sites and fusion of viral and host membranes. All these mechanisms allow the influenza virus to survive in humans, probably perpetually.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3591816     DOI: 10.1016/0002-9343(87)90554-7

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

1.  Evidence of recombination among enteroviruses.

Authors:  J Santti; T Hyypiä; L Kinnunen; M Salminen
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

Review 2.  New aspects of influenza viruses.

Authors:  M W Shaw; N H Arden; H F Maassab
Journal:  Clin Microbiol Rev       Date:  1992-01       Impact factor: 26.132

3.  The mucosal and systemic immune responses elicited by a chitosan-adjuvanted intranasal influenza H5N1 vaccine.

Authors:  Signe C Svindland; Åsne Jul-Larsen; Rishi Pathirana; Solveig Andersen; Abdullah Madhun; Emanuele Montomoli; Inderjit Jabbal-Gill; Rebecca J Cox
Journal:  Influenza Other Respir Viruses       Date:  2011-07-12       Impact factor: 4.380

Review 4.  Guidelines on management of human infection with the novel virus influenza A (H1N1)--a report from the Hospital das Clínicas of the University of São Paulo.

Authors:  Ludhmila Abrahao Hajjar; Denise Schout; Filomena Regina Barbosa Gomes Galas; David Everson Uip; Anna Sara Shafferman Levin; Helio Hehl Caiaffa Filho; Pedro Takanori Sakane; Carlos Alberto Suslik; Jose Manoel de Camargo Teixeira; Eloisa Bonfa; Antonio Alci Barone; Milton de Arruda Martins; Marcos Boulos; Jose Otavio Costa Auler
Journal:  Clinics (Sao Paulo)       Date:  2009       Impact factor: 2.365

Review 5.  Clinical review: update of avian influenza A infections in humans.

Authors:  Christian Sandrock; Terra Kelly
Journal:  Crit Care       Date:  2007       Impact factor: 9.097

Review 6.  Current recommendations for the prevention and treatment of influenza in the older population.

Authors:  P A Gross
Journal:  Drugs Aging       Date:  1991 Nov-Dec       Impact factor: 3.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.